

THIS IS A PATENT APPLICATION OF

SHAILENDRA K. SAXENA, Ph.D.

141 OLD SHORT HILLS ROAD, APT. 59

5

WEST ORANGE NJ 07052-1072

A CITIZEN OF THE UNITED STATES OF AMERICA

ENTITLED

10

RIBONUCLEASES AND METHODS OF MAKING THEM RECOMBINANTLY

PREPARED BY:

15

MARK H. JAY, ESQ.

MARK H. JAY, P.A.

CUSTOMER NUMBER 20439

RIBONUCLEASES
AND METHODS OF MAKING THEM RECOMBINANTLY

Background of the Invention

5 The invention relates to pharmaceuticals, and more particularly relates to pharmaceuticals for treating tumors in humans. In its most immediate sense, the invention relates to bioactive ribonucleases ("RNases").

 Some RNases are known to be active against certain
10 human tumor cells. For example, commonly-owned U.S. Patent No. 5,559,212 discloses and claims ranpirnase, an RNase pharmaceutical that is presently known by the registered trademark ONCONASE and that is presently the subject of Phase III clinical trials. And, commonly-
15 owned Patent No. US 6,239,257 B1 discloses four RNase proteins that belong to the pancreatic RNase A superfamily, each possessing activity against two human carcinoma cell lines.

 Attention is now being directed to "targeting"
20 pharmaceuticals to deliver them to particular cell receptors of interest. This is accomplished by selecting a targeting moiety that is preferentially attracted to the desired cell receptor and attaching (as by conjugation or fusion) the targeting moiety to the
25 pharmaceutical.

 Commonly-owned Patent No. US 6,175,003 B1 discusses the concept of targeting therapeutically active RNases by "cysteinizing" them. In the case of ranpirnase, this can be accomplished by conjugating the targeting moiety to
30 the cysteine residue at position 72. While this approach is promising and is still under investigation, some people believe that it may be difficult to obtain regulatory approval for a conjugate and that a fusion protein would have an easier path to regulatory approval.

The N-terminal residue of ranpirnase is pyroglutamic acid. This "blocks" the N-terminal, i.e. makes it impossible to attach other amino acid residues to the left of the N-terminal. For this reason, it is not possible to create a fusion protein by attaching a targeting moiety to the N-terminal of ranpirnase. And, while it is possible to remove the pyroglutamic acid residue and to attach a targeting moiety to the aspartic amino acid residue in the second position of ranpirnase, removal of the pyroglutamic acid residue eliminates the bioactivity of ranpirnase.

However, the RNases disclosed in the above-referenced Patent No. US 6,239,257 B1 are not only active against certain human cancer cells, but also lack "blocked" N-terminals. For this reason, each of these RNases could be used to make a targeted fusion protein by attaching a targeting moiety to its N-terminal end.

It would be advantageous to provide methods for manufacturing such proteins recombinantly.

It would further be advantageous to provide bioactive proteins that could be made into targeted fusion proteins.

In accordance with one aspect of the invention, methods are provided for recombinantly manufacturing the proteins disclosed in Patent No. US 6,239,257 B1.

In accordance with another aspect of the invention, new proteins are provided that possess activity against human carcinoma cells and that can also be manufactured recombinantly. One of the proteins is "cysteinized" to permit easier conjugation to a targeting moiety.

When recombinantly manufactured, one of the proteins disclosed in Patent No. US 6,239,257 B1 retains its activity against human carcinoma cells even when a number of different leader sequences are attached to its N-

terminal. The leader sequences form parts of the vector in which the DNA of the protein of interest has been inserted. As will be seen below, there is a compelling body of evidence that such leader sequences do not, when
5 attached to the N-terminal of any one of the family of RNase proteins disclosed in Patent No. US 6,239,257 B1, affect the bioactivity of the protein.

Brief Description of the Drawings

The invention will be better understood with
10 reference to the following exemplary and non-limiting drawings, in which:

Fig. 1 is a flow chart illustrating the process for recombinantly manufacturing the protein identified as 2325p4 in Patent No. US 6,239,257 B1;

15 Fig. 2 is a flow chart illustrating the process for recombinantly manufacturing the protein identified as 2325p6 in Patent No. US 6,239,257 B1;

Fig. 3 is a flow chart illustrating the process for recombinantly manufacturing the protein identified as
20 2728 in Patent No. US 6,239,257 B1;

Fig. 4 is a flow chart illustrating the process for manufacturing pET22b-2325p4 DNA;

Fig. 5 is a flow chart illustrating the process for recombinantly manufacturing the protein identified as
25 2325p4a in Patent No. US 6,239,257 B1;

Fig. 6 is a flow chart illustrating the process for recombinantly manufacturing 2325p4-Cys71 protein; and

Fig. 7 is a flow chart illustrating the process for manufacturing hEGF-linker-2325p4-Cys71 fusion protein.

30 Detailed Description of Preferred Embodiments

A common procedure is used in the following Examples 1, 2, and 3, which relate to recombinant production of proteins identified as 2325p4, 2325p6, and 2728 in Patent No. US 6,239,257 B1. This procedure will be described

first at a general level and then in more detail.
Thereafter, each Example will be given.

At a general level, fourteen oligonucleotides for each gene (seven representing the top DNA strand and
5 seven for the bottom DNA strand) were synthesized. The oligonucleotides were cautiously designed so that:

- a) after annealing, complementary oligonucleotides had an overhang at the 5' end of each pair, each such overhang being 7 oligonucleotides long; and
- 10 b) each such overhang had at least three nucleotide mismatches with the overhang of an unfitting pair of oligonucleotides.

Seven pairs of oligonucleotides, representing both strands of the full-length gene, were obtained after
15 annealing. The duplex oligonucleotides were ligated in three steps to form full-length DNA of the protein of interest. This full-length DNA was then subjected to PCR. The PCR primers were chosen to:

- a) incorporate a XbaI restriction site at the 5' end
20 of the gene and a BamHI restriction site at the 3' end of the gene. These sites were selected so the DNA could be cloned into a pET-11d plasmid vector at these sites.
- b) include a translation initiation codon immediately
25 before the first nucleotide of the gene.
- c) incorporate a translation termination codon immediately after the last nucleotide of the final codon of the gene.

The purified gene thus produced was inserted into a
30 pET11d plasmid vector between XbaI and BamHI restriction sites. The insert positive clones were identified and used to express recombinant protein.

In each instance, the expressed protein had an additional methionine residue at position -1. This was

cleaved in vitro using Aeromonas aminopeptidase to yield the desired protein.

- 5 More specifically, in each instance fourteen oligonucleotides were synthesized and gel purified by Genosys Biotechnologies, Inc. (The Woodlands, Texas). Each oligonucleotide was phosphorylated at its 5' end using T4 polynucleotide kinase enzyme and its reaction buffer from New England Biolabs, Inc. (Beverly, Massachusetts). The desired DNA was extracted with 10 Phenol:Chloroform solution (Eastman Kodak Company, Rochester, NY) and unincorporated rATP was removed by ethanol precipitation.

- Each solution of complementary oligonucleotides (20 µg each, for a total of 40 µg) was mixed and annealed to form duplex oligonucleotides. Annealing was carried out 15 by placing a tube containing the complementary oligonucleotides in a beaker containing boiling water and then transferring the beaker to a cold room for approximately 18 hours with gentle stirring.

- 20 The annealed duplex oligonucleotides were then agarose gel purified using a Jetsorb DNA extraction kit from Genomed Inc. (Research Triangle Park, North Carolina). The duplex oligonucleotides (approximately 10 µg each) were mixed and ligated together in three 25 separate ligation steps at 16 °C for 18 hours using T4 DNA ligase enzyme from New England Biolabs, Inc. (Beverly, Massachusetts). As above, the DNA in each ligation reaction mixture was precipitated with ethanol after extracting it with Phenol:Chloroform solution.

- 30 This produced full-length double stranded DNA of the protein of interest. This product, which was the desired gene, was amplified using PCR and purified from agarose gel using a Jetsorb DNA extraction kit. The purified gene was then

digested with XbaI and BamHI restriction enzymes followed by its ligation into a pET11d plasmid vector (Novagen) that had also been digested with XbaI and BamHI restriction enzyme from Stratagene (La Jolla, California). (It will be understood that the use of a pET11d vector, and of XbaI and BamHI restriction sites, is only preferred and not necessary. Another vector, and other restriction sites, could be used instead.)

Then, the ligated reaction mixture was used to transform E.coli strain XL1-Blue (Stratagene) competent cells. The clones were identified for the insert DNA of the desired protein in the plasmid DNA preparations by restriction enzyme analysis. The recombinant plasmid DNA was then used as described below to transform the expression host to express the target gene.

E.coli BL21(DE3) competent cells (Novagen, Madison, WI) were used as an expression host and transformed with the plasmid DNA. (Another expression host could have been used instead.) The recombinant protein was expressed by induction with IPTG. Most of the expressed protein was found in the inclusion bodies and some was also present in the soluble fraction.

To purify the recombinant protein, the bacterial pellet containing the inclusion bodies was resuspended, sonicated and centrifuged using the procedure of Schultz and Baldwin (Protein Science 1, 910-916, 1992), modified as discussed below. The inclusion bodies were washed with 50 mM Tris-HCl buffer, pH 8.5 containing 300 mM sodium chloride and centrifuged. The proteins present in the pellet were then denatured with 6 M guanidine-HCl in 100 mM Tricine buffer, pH 8.5. Thereafter, the proteins were reduced and fully unfolded by adding 0.1 M reduced glutathione followed by incubation at room temperature under nitrogen for 3 h. Then, the proteins were refolded

by 10 times dilution with nanopure water followed by incubation at 4-5 °C for 18h. The refolded protein was then purified by cation exchange chromatography on SP-Sepharose. The SP-Sepharose column was eluted with a linear sodium chloride gradient (0-0.3 M) in 0.15 M sodium acetate buffer, pH 5.0. Finally, the homogeneity of the purified proteins was checked by 10-20% SDS-polyacrylamide gel electrophoresis. Although these steps were preferred to increase the yield of the desired protein, they are not necessary to the invention and may be omitted.

Finally, as stated above, the initial methionine residue at position -1 was cleaved in vitro by Aeromonas aminopeptidase. This produced the desired protein.

15

Example 1: Synthesis, Cloning, and Expression of pET11d-2325p4 Plasmid DNA

Example 1 relates to a protein identified as 2325p4 in Patent No. US 6,239,257 B1, which has the amino acid sequence of SEQ ID NO:1 and the nucleotide sequence of SEQ ID NO:2.

In an initial step, oligonucleotides SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16 were synthesized and purified as discussed above.

In the next step (shown at the top of Fig. 1 and described in detail above), pairs of oligonucleotides were mixed and annealed to form duplex oligonucleotides A1, A2, A3, A4, A5, A6, and A7.

These annealed oligonucleotides A1, A2, A3, A4, A5, A6, and A7 were then agarose gel purified as discussed

above. The annealed and purified oligonucleotides were then mixed and ligated together in three separate ligation steps shown in the center of Fig. 1 using the procedure described above. This produced full-length

5 DNA.

1 μ g of the full-length DNA was subjected to PCR with primers SEQ ID NO:3 and SEQ ID NO:16. As discussed above, the primers provide XbaI and BamHI restriction sites permitting the gene to be inserted in a pET11d
10 vector.

The gene of the 2325p4 protein was agarose gel purified as discussed above. The purified 2325p4 gene was then digested with XbaI and BamHI restriction enzyme and ligated into a pET11d plasmid vector as discussed
15 above.

Then, as discussed above, the ligated reaction mixture was used to transform E.coli XL1-Blue competent cells, and the recombinant plasmid pET11d-2325p4 DNA was then used to transform the expression host to express the
20 target gene as discussed above.

The expressed protein has the amino acid sequence shown in SEQ ID NO:59, in which an additional N-terminal methionine residue is followed by lysine, the first amino acid of the 2325p4 protein. The N-terminal additional
25 methionine residue was cleaved as stated above to yield 2325p4 recombinant protein having the amino acid sequence SEQ ID NO:1.

As stated in Patent No. US 6,239,257 B1, 2325p4 protein inhibited growth of human submaxillary gland
30 carcinoma (A-253) cells and human bladder carcinoma (T-24) cells.

Example 2: Synthesis, Cloning, and Expression of
pET11d-2325p6 Plasmid DNA

Example 2 relates to a protein identified as 2325p6
5 in Patent No. US 6,239,257 B1, which has the amino acid
sequence of SEQ ID NO:17 and the nucleotide sequence of
SEQ ID NO:18.

In an initial step, oligonucleotides SEQ ID NO:19,
SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23,
10 SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27,
SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31,
and SEQ ID NO:32 were synthesized and purified as
discussed above.

In the next step (shown at the top of Fig. 2 and
15 described in detail above), pairs of oligonucleotides
were mixed and annealed to form duplex oligonucleotides
A8, A9, A10, A11, A12, A13, and A14.

These annealed oligonucleotides A8, A9, A10, A11,
A12, A13, and A14 were agarose gel purified as discussed
20 above. The annealed oligonucleotides were mixed and
ligated together in three separate ligation steps shown
in the center of Fig. 2 using the procedure described
above. This produced full-length DNA.

1 µg of the full-length DNA was subjected to PCR
25 with primers SEQ ID NO:32 and SEQ ID NO:33. As discussed
above, the primers provide XbaI and BamHI restriction
sites permitting the gene to be inserted into a pET11d
plasmid vector.

The double stranded full-length PCR product, namely
30 the gene of the 2325p6 protein, was purified from agarose
gel and ligated into a pET-11d plasmid vector at XbaI and
BamHI restriction site, all using the procedure discussed
above.

Then, using the same procedure described above, E.coli XL1-Blue competent cells were transformed and the recombinant plasmid pET11d-2325p6 DNA was used to transform the expression host (E.coli BL21(DE3) competent cells) to express the target gene.

The expressed protein has the amino acid sequence shown in SEQ ID NO:60, in which an additional N-terminal methionine amino acid is followed by lysine, the first amino acid of the 2325p6 protein. The N-terminal additional methionine residue was cleaved as stated above to yield 2325p6 recombinant protein having the amino acid sequence SEQ ID NO: 17.

As stated in Patent No. US 6,239,257 B1, 2325p6 protein inhibited growth of human submaxillary gland carcinoma (A-253) cells and human bladder carcinoma (T-24) cells.

Example 3: Synthesis, Cloning, and Expression of pET11d-2728 Plasmid DNA

Example 3 relates to a protein identified as 2728 in Patent No. US 6,239,257 B1, which has the amino acid sequence of SEQ ID NO:34 and the nucleotide sequence of SEQ ID NO:35.

In an initial step, oligonucleotides SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, and SEQ ID NO:49 were synthesized and purified as discussed above.

In the next step (shown at the top of Fig. 3 and described in detail above), pairs of oligonucleotides were mixed and annealed to form duplex oligonucleotides A15, A16, A17, A18, A19, A20, and A21.

These annealed oligonucleotides A15, A16, A17, A18, A19, A20, and A21 were agarose gel purified as discussed above. The annealed oligonucleotides were mixed and ligated together in three separate ligation steps shown
5 in the center of Fig. 3 using the procedure described above. This produced full-length DNA.

1 µg of the full-length DNA was subjected to PCR with primers SEQ ID NO:33 and SEQ ID NO:49. As discussed above, the primers provide XbaI and BamHI restriction
10 sites permitting the gene to be inserted into a pET11d plasmid vector.

The double stranded full-length PCR product, namely the gene of the 2728 protein, was purified from agarose gel and ligated into a pET11d plasmid vector, all using
15 the procedure described above.

Then, using the same procedure described above, E.coli XL1-Blue competent cells were transformed and the recombinant plasmid DNA pET11d-2728 was used to transform the expression host cell (E.coli BL21(DE3) competent
20 cells) to express the target gene.

The expressed protein has the amino acid sequence shown in SEQ ID NO: 61, in which an additional N-terminal methionine amino acid is followed by lysine, the first amino acid of the 2728 protein. The N-terminal
25 additional methionine residue was cleaved as stated above to yield 2728 recombinant protein having the amino acid sequence SEQ ID NO: 34.

As stated in Patent No. US 6,239,257 B1, 2728 protein inhibited growth of human submaxillary gland
30 carcinoma (A-253) cells and human bladder carcinoma (T-24) cells.

Example 4: Synthesis and Cloning of pET22b-2325p4 DNA

As stated above, the protein identified as 2325p4 in Patent No. US 6,239,257 B1 has the amino acid sequence of SEQ ID NO:1 and the nucleotide sequence of SEQ ID NO:2. The process for making pET22b-2325p4 DNA is illustrated in Fig. 4.

The above-described pET11d-2325p4 plasmid DNA (consisting of 2325p4 DNA cloned in a pET-11d vector) was used as a template for amplification using forward and reverse DNA primers in PCR to produce 2325p4 DNA in a form suitable for cloning into a pET22b plasmid between the MscI and BamHI restriction sites.

The forward primer, which is constructed to have SEQ ID NO:50, was designed to incorporate a MscI restriction site at the 5' end of the gene. The reverse primer, which is constructed to have SEQ ID NO:16, was designed to have a stop codon flanked by a BamHI site at the 3' end of the gene. These primers were used in a single step of PCR amplification. The amplified DNA was then digested with MscI and BamHI restriction enzyme and cloned into pET22b plasmid digested with MscI and BamHI restriction enzymes. The newly constructed plasmid was named pET22b-2325p4 DNA.

25

Example 5: Synthesis, Cloning, and Expression of pET11d-2325p4a Plasmid DNA

pET11d-2325p4a DNA has been synthesized by replacing the isoleucine residue at position 44 of pET11d-2325p4 DNA with valine using site-directed mutagenesis. 2325p4a protein has the amino acid sequence of SEQ ID NO:51 and the nucleotide sequence of SEQ ID NO:52.

30

Primers were designed to generate DNA fragments containing a) an XbaI restriction site at the 5' terminus and b) a stop codon flanked by a BamHI site at the 3' terminus, and mismatched primers were synthesized to
5 change the isoleucine residue at position 44 to valine. The full-length gene of 2325p4a was made in two steps of PCR amplifications using a Perkin Elmer DNA thermal cyclers, PCR reagents and DNA polymerase.

In the first step of PCR amplification as shown in
10 Fig. 5, two separate PCR reactions were performed using pET11d-2325p4 DNA as a template. In the first PCR reaction, amplification was carried out using primers SEQ ID NO:33 and SEQ ID NO:54 and in the second PCR reaction, amplification was carried out using primers SEQ NO ID:16
15 and SEQ ID NO:53. These two PCR reactions resulted in two overlapping DNA fragments, both bearing the same mutation in the overlapping region introduced via primer mismatch.

In the second step of PCR amplification, the two
20 overlapping half-fragments were mixed together with primers SEQ ID NO:33 and SEQ ID NO:16 to produce full-length 2325p4a DNA containing the desired mutation. Then, the amplified full-length 2325p4a DNA was gel purified and digested with XbaI and BamHI restriction
25 enzymes and subsequently cloned into pET11d plasmid cut with XbaI and BamHI restriction enzymes. The newly constructed plasmid was named pET11d-2325p4a DNA.

Recombinant 2325p4a protein was expressed and purified using E.coli BL21(DE3) competent cells in the
30 same way as described above in Examples 1, 2, and 3. The protein as expressed has the amino acid sequence of SEQ ID NO: 68, with an initial methionine residue that is cleaved in vitro using Aeromonas aminopeptidase to yield

the protein having the amino acid sequence SEQ ID NO: 51.
This protein is active against A-253 cells.

Example 6: Synthesis, Cloning, and Expression of pET11d-
5 2325p4-Cys71 DNA

Commonly-owned Patent No. US 6,175,003 B1 discusses
the concept of "cysteinizing" therapeutically active
RNases. It would be advantageous to "cysteinize" the
10 2324p4 protein disclosed in the above-referenced '257
patent to facilitate conjugation of a targeting moiety
thereto. The 2325p4 protein has now been cysteinized by
replacing the threonine residue at position 71 with
cysteine using site-directed mutagenesis to form 2325p4-
15 Cys71, which has the amino acid sequence of SEQ ID NO: 55
and the nucleotide sequence of SEQ ID NO: 56.

Primers were designed to generate DNA fragments
containing a) an XbaI restriction site at the 5' terminus
and b) a stop codon flanked by a BamHI site at the 3'
20 terminus, and mismatched primers were synthesized to
change the threonine residue at position 71 to cysteine.
The full-length gene of 2325p4-Cys71 was made in two
steps of PCR amplifications using a Perkin Elmer DNA
thermal cycler, PCR reagents and DNA polymerase.

25 In the first step of PCR amplification as shown in
Fig. 6, two separate PCR reactions were performed using
pET11d-2325p4 DNA as a template. In the first PCR
reaction, amplification was carried out using primers SEQ
ID NO:33 and SEQ ID NO:58, and in the second PCR
30 reaction, amplification was carried out using primers SEQ
NO ID: 16 and SEQ ID NO:57. These two PCR reactions
resulted in two overlapping DNA fragments, both bearing
the same mutation in the overlapping region introduced
via primer mismatch.

In the second step of PCR amplification, the two overlapping half-fragments were mixed together with primers SEQ ID NO:33 and SEQ ID NO:16 to produce full-length 2325p4-Cys71 DNA containing the desired mutation.

5 Then, the amplified full-length 2325p4-Cys71 DNA was gel purified and digested with XbaI and BamHI restriction enzymes and subsequently cloned into pET-11d plasmid cut with XbaI and BamHI restriction enzymes. The newly constructed plasmid was named pET11d-2325p4-Cys71 DNA.

10 Recombinant 2325p4-Cys71 protein was expressed and purified using E.coli BL21(DE3) competent cells in the same way as described above in Examples 1, 2, and 3. The protein as expressed has the amino acid sequence of SEQ ID NO: 69, with an initial methionine residue that is
15 cleaved in vitro using Aeromonas aminopeptidase to yield the protein having the amino acid sequence SEQ ID NO: 55. This protein is active against A-253 cells.

Quite obviously, a targeting moiety can be conjugated to the cysteine residue at position 71 of the
20 2325p4-Cys71 protein to direct it to a particular cell receptor of interest. The selection of an appropriate moiety is within the skill of a person skilled in the art.

25 Example 7: Synthesis, Cloning, and Expression of pET22b-hEGF-linker-2325p4-Cys71 Plasmid DNA

A fusion gene (hEGF-linker-2325p4-Cys71 DNA) cloned in pET22 plasmid vector has been synthesized and expressed.
30 The recombinantly produced hEGF-linker-2325p4-Cys71 fusion protein has the amino acid sequence of SEQ ID NO:70 and the nucleotide sequence of SEQ ID NO:71.

SEQ ID NO:70 is 176 residues long, and consists of:
a) the sequence of hEGF protein (residues 1 to 53);

- b) the sequence of the Linker(residues 54 to 62); and
- c) the sequence of the 2325p4-Cys71 protein sequence (residues 63 to 176)

The full-length gene of hEGF-linker-2325p4-Cys71 was synthesized as shown in Fig. 7, using three steps of PCR amplification carried out using a Perkin Elmer DNA thermal cycler, PCR reagents, and DNA polymerase. pET22b-hEGF DNA and pET11d-2325p4-Cys71 DNA were used as templates for amplification.

10 In the first step of PCR amplification, the plasmid pET22b-hEGF DNA was used as a template for amplification using primers SEQ ID NO:72 and SEQ ID NO:74. The primer of SEQ ID NO:74 has the C-terminal nucleotide sequence of hEGF, followed by the nucleotide sequence of the linker.

15 In the second step of PCR the plasmid pET11d-2325p4-Cys71 DNA was used as a template for amplification using primers SEQ ID NO:16 and SEQ ID NO:73. As stated above, the primer of SEQ ID NO:16 was designed to generate a stop codon flanked by a BamHI site at the 3' terminus.

20 The primer of SEQ ID NO:73 contains the nucleotide sequence of the linker, followed by the N-terminal nucleotide sequence of 2325p4-Cys71 DNA.

These two PCR reactions resulted in two overlapping DNA fragments. In the third PCR step, these two overlapping fragments were mixed together with primer SEQ ID NO:72 and SEQ ID NO:16 to produce full-length hEGF-linker-2325p4-Cys71 DNA. The amplified full-length hEGF-linker-2325p4-Cys71 DNA was agarose gel purified as above, digested with BamHI restriction enzyme, and finally ligated into pET22b plasmid cut with MscI and BamHI restriction enzymes.

The newly constructed plasmid was named pET22b-hEGF-linker-2325p4-Cys71 DNA.

E.coli BL21(DE3) competent cells were transformed with pET22b-hEGF-linker-2325p4-Cys71 plasmid DNA and the recombinant protein was expressed and as in Examples 1, 2, and 3 above. The protein as expressed has the amino acid sequence of SEQ ID NO: 70. This protein is active against A-253 cells.

Example 8: Expression of Proteins from pET22b-2325p4 Plasmid

10

A surprising result occurred when the 2325p4 protein was expressed in E.coli BL21(DE3) competent cells from pET22b-2325p4 plasmid as discussed above in Example 1. Four separate bioactive proteins were expressed, and all of them were active against A-253 cells. The first of these was the 2325p4 protein, which has the amino acid sequence shown in SEQ ID NO:1.

The second protein was the 2325p4 protein preceded by a two residue long leader sequence having the amino acid sequence of SEQ ID NO:62 (the second protein therefore has the amino acid sequence of SEQ ID NO:63). The third protein was the 2325p4 protein preceded by a seven residue long leader sequence having the amino acid sequence of SEQ ID NO:64 (the third protein therefore has the amino acid sequence of SEQ ID NO:65). The fourth protein was the 2325p4 protein preceded by a twenty-two residue long leader sequence having the amino acid sequence of SEQ ID NO:66 (the fourth protein therefore has the amino acid sequence of SEQ ID NO: 67). Each of these leader sequences is derived from the pelB leader sequence of the pET22b vector.

To a person skilled in the art, the fact that all four of these proteins remained active is very strong evidence that any protein made up of the 2325p4 protein

preceded by at least one and at most all of the residues in the seven residue long leader sequence of SEQ ID NO:64 in order will be active as well. And, the same is true of any protein made up of the 2325p4 protein preceded by
5 at least one and at most all of the residues in the twenty two residue long leader sequence of SEQ ID NO:66 in order. In other words, since the leader sequences of SEQ ID NO:64 and SEQ ID NO:66 did not affect the activity of the 2325p4 protein, any person ordinarily skilled in
10 the art would expect that shortened versions of these leader sequences would, when likewise attached at the N-terminal end of the 2325p4 protein, leave the bioactivity of the 2325p4 protein unaffected.

Furthermore, given that the 2325p6 and 2728 proteins
15 are also active against A-253 and T-24 cells, a person skilled in the art would conclude that adding all or any similarly-shortened shortened part of the SEQ ID NO:64 or the SEQ ID NO:66 leader sequences to the N-terminal end of the 2325p4 protein, to the N-terminal end of the
20 2325p6 protein, or to the N-terminal end of the 2728 protein, would also produce a bioactive protein. This is because these proteins are highly homologous and have highly similar activities against the same cancer cells.

Although one or more preferred embodiments have been
25 described above, the invention is defined only by the following claims: